NCT04921358sitravatinibtislelizumabdocetaxel
…ercome resistance to anti-PD-(L)1 therapy.Methods SAFFRON-301 ( NCT04921358) was an open-label, randomised, phase III trial enrolling patie…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04921358 ×
NCT04921358
This institution is selected. Its supporting articles are shown below.